The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects

University at Buffalo22 enrolled

Overview

Sitagliptin is a new oral hypoglycemic anti-diabetic drug used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. Sitagliptin has been shown to have fewer side effects in the control of blood glucose values. Obesity and diabetes are states of increased inflammation and can influence the free radicals and inflammatory markers (chemicals in the blood which increase due to inflammation in the body) and are also major risk factors for atherosclerotic disease. In this study we want to see the effect of sitagliptin on these markers. We believe that Sitagliptin may exert an anti-inflammatory effect in the human. The purpose of this study is to determine if the addition of sitagliptin to diabetic patients will provide added benefit. We believe that sitagliptin provides these added benefits by suppressing free radicals (charged substances that cause damage to the body) and inflammation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Type 2 Diabetes

Interventions

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males or females with age 20-75 years inclusive. * Type 2 diabetes * Males and Females BMI \> 30 * Subjects on statins, ACE inhibitors, thiazolidenediones and antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the course of study. * BP under control -No change required to BP medications * HbA1c \> 7% Exclusion Criteria: * Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks * Pregnancy * Hepatic disease (abnormal LFT's),Renal impairment (serum creatinine \> 1.5), * Participation in any other concurrent clinical trial * Any other life-threatening, non-cardiac disease, * Uncontrolled hypertension (BP \> 160/100 mm of Hg) * Congestive Heart Failure * Use of an investigational agent or therapeutic regimen within 30 days of study * Subjects on Exenatide, incretin or insulin therapy

Outcomes

Primary Outcomes

Change in Reactive Oxygen Species (ROS) Generation by MNC, Protein and mRNA Expression of p47phox Subunit of NADPH Oxidase, in MNC's of Obese Type 2 Diabetic Patients

Time frame: 12 weeks

Secondary Outcomes

Change in Oxidative Stress From Baseline to 12 Weeks

To investigate that therapy with sitagliptin orally daily (100 mg) for 12 weeks decreases oxidized lipids (9-hydroxyoctadecadienoicacid (9-HODE) and 13-HODE) in plasma and F2-isoprostane in urine of obese type 2 diabetic patients Outcome measures given are calculated from the baseline - 12 weeks.

Time frame: value at 12 weeks minus value at baseline